Chuamsaamarkkee K.Charoenphun P.Amnuaywattakorn S.Sakulpisuti C.Thamnirat K.Chamroonrat W.Mahidol University2025-10-202025-10-202025-12-01Egyptian Journal of Radiology and Nuclear Medicine Vol.56 No.1 (2025)0378603Xhttps://repository.li.mahidol.ac.th/handle/123456789/112663Background: Implementing multiple time-point dosimetry in clinical settings faces limitations due to the imaging burden, increased workload, and additional costs. Single time-point (STP) dosimetry has emerged as a critical technique for calculating radiation doses efficiently. It has been suggested that 48 hours post-administration is preferred as the optimal imaging time for determining the absorbed doses in the kidneys and tumours for metastatic castration-resistant prostate cancer (mCRPC) patients treated with ¹⁷⁷Lu-PSMA. This study aimed to evaluate a phantom study for fast SPECT acquisition and its clinical integration using STP dosimetry in ¹⁷⁷Lu-PSMA mCRPC patients. Methods: Phantom and patient acquisitions were conducted using a dual-head SPECT/CT GE Discovery 870 DR equipped with an MEGP collimator. Fast SPECT acquisition was quantitatively optimised and calibrated at 5 seconds per frame over 60 frames per head, totalling 7 minutes per bed, using the Jaszczak phantom with known ¹⁷⁷Lu activity. Images were quantitatively reconstructed using OSEM iterative reconstruction (16 iterations, 9 subsets, 128x128 matrix size) with Hybrid Recon 3.0. Whole-body SPECT/CT scans of eight treatment cycles (five patients), administered 5.6 – 8.1 GBq (mean of 6.8 GBq) of ¹⁷⁷Lu-PSMA I&T, were imaged at approximately 48 hours post-administration. STP voxel-based dosimetry was performed to calculate the absorbed doses in the kidneys and tumours using the Hanscheid method in Hermes Dosimetry Software. Results: The mean absorbed doses in the kidneys were 2.04 ± 0.37 Gy, confirming that the total absorbed dose delivered to the kidneys remained within the acceptable limit of 23 Gy. The tumours (n=25) showed absorbed doses ranging from 0.98 – 16.05 Gy. Notably, different tumour sites exhibited significant variation in absorbed doses, with most of tumours receiving higher doses compared to the kidneys. Conclusions: STP dosimetry for ¹⁷⁷Lu-PSMA, coupled with fast SPECT acquisition, demonstrates significant potential for clinical application. The successful transition from phantom studies to clinical settings marks a pivotal development towards more efficient and less time-consuming dosimetric practices in nuclear medicine, potentially improving patient care by reducing the imaging and procedural burden.MedicineArticleSCOPUS10.1186/s43055-025-01596-w2-s2.0-10501861752820904762